miR-20a-5p inhibits endometrial cancer progression by targeting janus kinase 1

Ying He1, Hui Ma1, Jing Wang1

  • 1Department of Gynaecology, The First Affiliated Hospital of Hebei North University, Zhangjiakou, Hebei 075000, P.R. China.

Oncology Letters
|April 14, 2021
PubMed

Insights

MicroRNA-20a-5p (miR-20a-5p) is downregulated in endometrial cancer (EC), acting as a tumor suppressor by inhibiting janus kinase 1 (Jak1). This finding suggests miR-20a-5p and Jak1 as potential EC therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Endometrial cancer (EC) pathogenesis is complex and not fully understood.
  • The role of microRNA-20a-5p (miR-20a-5p) in EC progression remains unclear.
  • Investigating microRNAs offers potential for novel diagnostic and therapeutic strategies in cancer.

Purpose of the Study:

  • To analyze the association between miR-20a-5p expression and clinicopathological characteristics in EC patients.
  • To determine if miR-20a-5p inhibits EC progression by targeting janus kinase 1 (Jak1).
  • To elucidate the functional mechanism of miR-20a-5p in endometrial cancer.

Main Methods:

  • Reverse transcription quantitative PCR and western blotting to assess miR-20a-5p and Jak1 expression in EC tissues.
  • Cellular assays (MTT, Matrigel invasion, adhesion) to evaluate the impact of miR-20a-5p on EC cell behavior.
  • Dual luciferase reporter assay to confirm direct targeting of Jak1 by miR-20a-5p.

Main Results:

  • miR-20a-5p was significantly downregulated, while Jak1 was upregulated in EC tissues compared to adjacent normal tissues.
  • A negative correlation was observed between miR-20a-5p and Jak1 expression in EC tissues.
  • miR-20a-5p expression correlated significantly with myometrial invasion depth, FIGO stage, histologic grade, and lymph node metastasis.
  • Jak1 was validated as a direct target of miR-20a-5p, and its overexpression reversed miR-20a-5p-mimic effects on EC cell proliferation and invasion.

Conclusions:

  • miR-20a-5p functions as a tumor suppressor in endometrial cancer, partly by downregulating Jak1 expression.
  • miR-20a-5p expression is significantly associated with key clinicopathological features of EC.
  • Both miR-20a-5p and Jak1 represent promising therapeutic targets for endometrial cancer treatment.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.4K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
22.8K
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.4K